Research analysts at StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Rating) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.
Ampio Pharmaceuticals Stock Performance
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.
- Get a free copy of the StockNews.com research report on Ampio Pharmaceuticals (AMPE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.